E-DRUG: Invitation to Paris R&D Meeting -- October 15
-----------------------------------------------------
INVITATION TO PARTICIPATE IN OPEN SESSION
DRUGS FOR COMMUNICABLE DISEASES
STIMULATING DEVELOPMENT AND SECURING AVAILABILITY
OCTOBER 15, 1999 14.00 - 18.30
L'ORANGERAIE / PARIS
A conference convened by the Medecins Sans Frontieres Foundation in
collaboration with the World Health Organisation and with the support
of the Rockefeller Foundation.
Therapeutic options for treating life-threatening communicable
diseases (infectious and parasitic) are extremely limited. While the
commercial drug industry has been prolific, development of new
treatments for diseases that kill millions of people in poor countries
has been sparse. Of the 1,233 new chemical entities that were
registered by Western health authorities between 1975-1997, only 11
were specifically indicated for tropical diseases.
Currently, companies deploy research and development funds where they
can realise the greatest financial return. In practice, this means
that more money is spent researching lifestyle diseases such as
obesity and impotence than global health threats such as tuberculosis
and malaria.
The Open Session will follow a professional workshop that is being
convened to search for ways to repair the links that have been broken
between research, development and marketing. In the Open Session
experts will report on findings from the workshop and then
representatives from industry and international organisations will
address their role in developing the next generation of effective
communicable disease treatments.
Who Should Attend:
Representatives from academia, governments, industry, non-government
organisations, and the press with an interest in international public
health.
The meeting will take place in English and French. Simultaneous
translation will be available
14.00 - 14.15 Welcome and Introduction
Moderator: Laurie Garrett (Newsday, USA)
14.15 - 15.15 Report-Outs From Expert Roundtables
Conclusions & Practical Implications
- Nick White (Mahidol University, Thailand)
- Pierre Ambroise-Thomas (Grenoble University,
France)
- Dyann Wirth (Harvard University, USA)
- Bernard P�coul (Director, Access to Essential
Medicines, MSF)
15.15 - 15.30 Solutions from Within
What developing countries need to augment their drug
development capability. Realistic short and long-term
goals
- NK Ganguly (Indian Council of Medical Research,
India)
15.30 - 15.45 A Scientist's Perspective
Role and responsibilities of the researcher in today's
market driven world
- Malcolm Molyneux (Director, Wellcome Trust
Research Laboratories, Malawi /Professor of
Tropical Medecine, School of Tropical Medecine,
UK)
15.45 - 16.15 Questions & Answers From Participants
16.15 - 16.45 Coffee Break
16.45 - 17.00 WHO's Role in Improving Drug Development
Defining priorities for the development of new drugs
for neglected diseases
- David Heymann (Director, Communicable Diseases
Cluster, WHO, Switzerland)
17.00 - 17.15 The World Bank's Point of View
How the bank can support countries in increasing
their capacity to develop drugs
- Ok Panenborg (The World Bank, USA)
17.15 - 17.30 Donor Country Role and Responsibilities
How can a market be created for communicable disease
treatments?
What role should donor countries play?
- Invited: Bruno Hansen (Director, DG XII,
European Commission, Belgium)
17.30 - 17.45 Pharmaceutical Industry: New Strategies
Lacking commercial incentives; new ideas for effective
collaboration
When is transfer of technology appropriate?
Trevor Jones (Director, The Association of the British
Pharmaceutical Industry,U.K.)
If you would like to attend the meeting please reply with your name
and organisation to:
Jean-Michel Piedagnel
tel: + 33 1 4021 2929
fax: + 33 1 4806 6868
e-mail : fondation@paris.msf.org
MSF - Fondation
8, rue Saint-Sabin
75544 PARIS cedex 11
FRANCE
The conference will take place:
L'ORANGERAIE / 17, Cit� Joly / 75011 PARIS / tel: + 33 1 4700 4313
Metro stations: line 3 - St-Maur / line 2 - P�re Lachaise
Daniel BERMAN
Email: Daniel_BERMAN@geneva.msf.org
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.